Department of Medico-Surgical Sciences and Biotechnologies, Faculty of Medicine and Pharmacy, Sapienza University, Polo Pontino, Corso Della Repubblica 79, Latina, Italy.
Clin Chim Acta. 2013 Oct 21;425:93-6. doi: 10.1016/j.cca.2013.07.014. Epub 2013 Jul 26.
Circulating free DNA (cfDNA) is present in higher concentration in non-small-cell lung cancer (NSCLC) patients than in controls. This study was designed to assess the sensitivity and specificity of Agilent 2100 Bioanalyzer to identify patients with NSCLC and to compare it with quantitative RealTime-PCR (RT-qPCR) assay. 30 NSCLC patients and 26 controls were analyzed. The amount of cfDNA was determined both through quantitative RT-PCR targeting the human β-actin gene and by Agilent 2100 Bioanalyzer. Performances of the assays were calculated by the receiver operating characteristic (ROC) curves. The mean cfDNA concentration, obtained through the use of Agilent 2100 Bioanalyzer, in NSCLC patients (94.5 ng/mL) was almost twice the concentration detected in controls (42.8 ng/mL) as well as found by RT-qPCR (22.5 ng/mL vs 7.1 ng/mL, p<0.001). The area under curve of Agilent 2100 Bioanalyzer and RT-PCR showed that there are no statistically significant differences between these tests (p<0.92). This study shows that Agilent 2100 Bioanalyzer is an effective diagnostic tool to discriminate NSCLC patients from healthy individuals and suggests a new approach for early detection of NSCLC.
循环游离 DNA（cfDNA）在非小细胞肺癌（NSCLC）患者中的浓度高于对照组。本研究旨在评估安捷伦 2100 Bioanalyzer 识别 NSCLC 患者的灵敏度和特异性，并将其与定量实时 PCR（RT-qPCR）检测进行比较。分析了 30 名 NSCLC 患者和 26 名对照者。通过针对人β-肌动蛋白基因的定量 RT-PCR 和安捷伦 2100 Bioanalyzer 测定 cfDNA 的量。通过接收者操作特性（ROC）曲线计算分析物的性能。通过安捷伦 2100 Bioanalyzer 获得的 NSCLC 患者的 cfDNA 浓度平均值（94.5ng/mL）几乎是对照组（42.8ng/mL）和 RT-qPCR 检测到的浓度（22.5ng/mL vs 7.1ng/mL，p<0.001）的两倍。Agilent 2100 Bioanalyzer 和 RT-PCR 的曲线下面积表明这些检测之间没有统计学上的显著差异（p<0.92）。这项研究表明，安捷伦 2100 Bioanalyzer 是一种有效的诊断工具，可将 NSCLC 患者与健康个体区分开来，并为 NSCLC 的早期检测提供了一种新方法。
